Differential Effects of IL-1 Alpha and IL-1 Beta on Tumorigenicity Patterns and Invasiveness
Overview
Authors
Affiliations
In this study, we show that distinct compartmentalization patterns of the IL-1 molecules (IL-1alpha and IL-1beta), in the milieu of tumor cells that produce them, differentially affect the malignant process. Active forms of IL-1, namely precursor IL-1alpha (pIL-1alpha), mature IL-1beta (mIL-1beta), and mIL-1beta fused to a signal sequence (ssIL-1beta), were transfected into an established fibrosarcoma cell line, and tumorigenicity and antitumor immunity were assessed. Cell lines transfected with pIL-1alpha, which expresses IL-1alpha on the membrane, fail to develop local tumors and activate antitumor effector mechanisms, such as CTLs, NK cells, and high levels of IFN-gamma production. Cells transfected with secretable IL-1beta (mIL-1beta and ssIL-1beta) were more aggressive than wild-type and mock-transfected tumor cells; ssIL-1beta transfectants even exhibited metastatic tumors in the lungs of mice after i.v. inoculation (experimental metastasis). In IL-1beta tumors, increased vascularity patterns were observed. No detectable antitumor effector mechanisms were observed in spleens of mice injected with IL-1beta transfectants, mock-transfected or wild-type fibrosarcoma cells. Moreover, in spleens of mice injected with IL-1beta transfectants, suppression of polyclonal mitogenic responses (proliferation, IFN-gamma and IL-2 production) to Con A was observed, suggesting the development of general anergy. Histologically, infiltrating mononuclear cells penetrating the tumor were seen at pIL-1alpha tumor sites, whereas in mIL-1beta and ssIL-1beta tumor sites such infiltrating cells do not penetrate inside the tumor. This is, to our knowledge, the first report on differential, nonredundant, in vivo effects of IL-1alpha and IL-1beta in malignant processes; IL-1alpha reduces tumorigenicity by inducing antitumor immunity, whereas IL-1beta promotes invasiveness, including tumor angiogenesis, and also induces immune suppression in the host.
Koning T, Calaf G Int J Mol Sci. 2024; 25(16).
PMID: 39201290 PMC: 11354366. DOI: 10.3390/ijms25168604.
Krishnamohan M, Kaplanov I, Maudi-Boker S, Yousef M, Machluf-Katz N, Cohen I Int J Mol Sci. 2024; 25(7).
PMID: 38612760 PMC: 11011794. DOI: 10.3390/ijms25073950.
Menchinskaya E, Dyshlovoy S, Venz S, Jacobsen C, Hauschild J, Rohlfing T Mar Drugs. 2024; 22(1).
PMID: 38248645 PMC: 10817243. DOI: 10.3390/md22010020.
Bjorner K, Chen W, Gannavarapu V, Axling F, Gulyas M, Halim M Ups J Med Sci. 2024; 28.
PMID: 38187473 PMC: 10770641. DOI: 10.48101/ujms.v128.10241.
Jhawar S, Wang S, Thandoni A, Bommareddy P, Newman J, Marzo A J Immunother Cancer. 2023; 11(7).
PMID: 37433716 PMC: 10347455. DOI: 10.1136/jitc-2023-006780.